CurrentBaylor Scott & White Health PlanPolicy 044

Hyperbaric Oxygen Therapy (HBOT)

Defines medical necessity, covered indications, exclusions, contraindications, and coding guidance for systemic hyperbaric oxygen therapy for members of Baylor Scott & White Health Plan (BSWHP). Applies across lines of business with Medicare/Medicaid references.

Policy Summary

PayerBaylor Scott & White Health Plan

PolicyHyperbaric Oxygen Therapy (HBOT)

Policy CodePolicy 044

Change TypeNo material changes

Effective Date04/01/2025

Next Review Date03/10/2026

Key ActionInitiate HBOT only after failure of an adequate ≥30-day course of standard wound therapy and document 30‑day wound evaluations showing improvement to continue treatment.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

~15+Listed covered indications

22+Unproven / excluded conditions

99183, G0277Key procedure codes

04/01/2025Effective

Coverage and Medical Necessity Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

General adjunctive coverage: HBOT is considered medically necessary for specific indications when other standard therapies have been unsuccessful and when used as an adjunct to standard care.

See list of specific indications in policy.

Listed covered indications: Acute carbon monoxide intoxication; Decompression illness; Gas gangrene (clostridial myositis/myonecrosis); Air or gas embolism; Acute traumatic peripheral ischemia; Acute peripheral arterial insufficiency; Crush injuries and suturing of severed limbs; Progressive necrotizing infections (necrotizing fasciitis); Chronic refractory osteomyelitis unresponsive to conventional management; Preparation/preservation of compromised skin grafts (not primary wound management); Osteoradionecrosis as an adjunct; Soft tissue radionecrosis as an adjunct; Actinomycosis refractory to conventional therapy; Carbon monoxide poisoning with cyanide exposure; Diabetic lower extremity wounds meeting specified criteria.

Individual indications enumerated in policy.

Diabetic lower extremity wounds criteria

Patient has type I or II diabetes with a lower extremity wound due to diabetes.
Wound is classified as Wagner grade III or higher.
Patient has failed an adequate course of standard wound therapy defined as no measurable signs of healing for at least 30 days of standard wound therapy.

BSWHP considers systemic hyperbaric oxygen therapy (HBOT) unproven and not covered for multiple conditions where evidence does not support superiority over conventional care. These listed exclusions include, but are not limited to: chronic peripheral vascular insufficiency; cutaneous, decubitus, and stasis ulcers; anaerobic or aerobic septicemia (other than clostridial); skin burns (thermal); senility; myocardial infarction; sickle cell anemia; cardiogenic shock; acute thermal/chemical pulmonary injury with insufficiency; acute or chronic cerebrovascular insufficiency; hepatic necrosis; nonvascular chronic brain syndromes (e.g., Pick’s, Alzheimer’s, Korsakoff’s); tetanus; organ transplantation or organ storage; exceptional blood loss anemia; pulmonary emphysema; multiple sclerosis; arthritic diseases; and acute cerebral edema.

The policy references bibliographic sources and evidence reviews that inform clinical assessment of HBOT (for example, technology assessments and systematic reviews listed from CADTH, AHRQ, and Cochrane). These excerpts provide background literature citations and do not themselves state additional coverage rules or criteria specific to BSWHP.

Topical oxygen delivery systems and topical application of oxygen are explicitly noted as non-covered in the policy context; systemic HBOT is distinguished from topical approaches. The policy also lists contraindications relevant to oxygen delivery, including the absolute contraindication of untreated tension pneumothorax and several relative contraindications (for example, untreated upper respiratory tract infection, emphysema with CO2 retention, uncontrolled hyperthermia, pregnancy, seizure disorder, claustrophobia, asymptomatic pulmonary lesions on chest x-ray, and history of thoracic or ear surgery).

Procedure and Diagnosis Coding Guidance

Covered CPT Codes / HBOT procedure codesCPTCovered

99183	Hyperbaric oxygen therapy
G0277	HBOT, full body chamber, 30m

CPT/HCPCS Codes Not Covered (Topical oxygen devices)HCPCSNot Covered

A4575	Topical hyperbaric oxygen chamber, disposable
E0446	Topical oxygen delivery system, not otherwise specified, includes all supplies and accessories

Applicable ICD-10 CodesICD-10

ICD-10 list per NCD 20.29

List of covered diagnoses per NCD 20.29 (referenced spreadsheet)

Standard wound therapy trial duration — key facts

Required trial durationAn adequate course of standard wound therapy defined as at least 30 consecutive days with no measurable signs of healing before HBOT is considered (>= 30 days)

Components of standard wound therapyIncludes vascular assessment/correction, nutritional optimization, glucose control, debridement, maintenance of a clean moist wound bed, appropriate off‑loading, and treatment of infection.

Documentation cadenceWounds must be evaluated at least every 30 days during HBOT administration; continued HBOT is not covered if no measurable healing within any 30‑day treatment period.

Provider Requirements, Prior Authorization, and Documentation

Prior Authorization

Prior authorization requirement — Not required (provider action highlight)

Prior authorization is not required for Hyperbaric Oxygen Therapy (HBOT). Providers should still review the member's Evidence of Coverage (EOC) or Summary Plan Description (SPD) to confirm benefit coverage and any plan-specific limitations before initiating services.

Prior Authorization: Not required
Action: Verify member EOC/SPD for benefit limitations and exclusions
Action: Confirm applicable ICD-10 diagnosis coding per Medicare NCD/LCD references and member plan

Step Therapy

Step: fail standard wound care before HBOT

Providers must ensure an adequate course of standard wound therapy has been completed prior to HBOT for diabetic lower extremity wounds. Failure to respond to standard wound care is defined as no measurable signs of healing for at least 30 consecutive days. Standard wound care includes vascular assessment and correction if possible, nutritional optimization, glucose control, debridement, maintenance of a clean moist granulation bed with appropriate dressings, appropriate off‑loading, and treatment of infection when present.

Requirement: Complete an adequate course (≥ 30 days) of standard wound therapy with no measurable healing before HBOT
Standard wound care elements: vascular assessment/correction; nutritional optimization; glucose control; debridement; moist dressings; off‑loading; infection management

Documentation Required

Wound evaluation and documentation cadence

Wounds undergoing HBOT must be evaluated at least every 30 days. Continued HBOT is not covered if measurable signs of healing are not demonstrated within any 30‑day treatment period.

Evaluation cadence: at least every 30 days during HBOT
Continuation rule: Discontinue if no measurable healing within any 30‑day period

Billing Rule

Benefit verification and diagnosis coding

Providers should verify member benefits and confirm appropriate diagnosis coding prior to billing. Refer to the member's EOC/SPD for coverage details and use applicable ICD‑10 codes aligned with Medicare NCD/LCD guidance where relevant. Inclusion of diagnosis codes in billing does not guarantee reimbursement; medical necessity criteria in this policy must be met.

Action: Verify benefits in member EOC/SPD before treatment
Action: Confirm and document ICD‑10 diagnosis codes consistent with coverage criteria and applicable NCD/LCD guidance
Note: Code inclusion does not guarantee payment; member must meet policy medical necessity

Step Therapy

Step therapy — no step therapy requirements described in these chunks

This policy does not impose any additional step‑therapy programs beyond the requirement to have failed an adequate course of standard wound care prior to HBOT. No other step therapy requirements are described.

No plan-level step therapy program for HBOT described beyond failure of standard wound care
Providers: follow the standard wound care failure requirement for diabetic lower extremity wounds

Denial Risk

No explicit denial triggers are stated

There are no explicit denial triggers listed in this policy excerpt. However, lack of measurable healing during any 30‑day HBOT interval, failure to meet the diabetic wound criteria (Wagner grade < III, non‑diabetic wound, or not having completed standard wound care), or lack of plan benefit coverage per the member's EOC/SPD may result in non‑coverage or denial.

No explicit denial triggers stated in the policy text
Potential denial risks: no measurable healing within 30 days, not meeting diabetic wound criteria, or benefits not covered per member EOC/SPD

Clinical Background and Scope

Hyperbaric oxygen therapy (HBOT) delivers 100% oxygen at elevated ambient pressure in a specialized chamber to increase tissue oxygen tension and support healing. It is used as an adjunctive therapy to standard medical and wound care when limb, function, or life is threatened or when wounds fail to heal after conventional therapy. The policy citations include systematic reviews and technology assessments that summarize HBOT’s proposed mechanisms and the clinical evidence base.

Key Definitions and Terms

Definition — Systemic HBOT

DefinitionSystemic HBOT is the administration of pure gaseous oxygen under pressures greater than one atmosphere in a specialized chamber to improve tissue oxygenation and promote healing.

Mechanism goalIncreases tissue oxygen tension and hydrostatic pressure to improve cellularity and vascularity and to reverse hypoxia.

SettingDelivered in a specialized hyperbaric chamber capable of exceeding 1 atmosphere absolute (ATA).

Definition — Failure to respond to standard wound care

DefinitionFailure to respond to standard wound care: no measurable signs of healing for at least 30 consecutive days despite standard wound therapy.

Implication for HBOTHBOT is considered only after this failure is documented; wounds must also be evaluated every 30 days during therapy.

Continued treatment ruleContinued HBOT is not covered if measurable signs of healing have not been demonstrated within any 30‑day treatment period.

Definition — Hyperbaric Oxygen Therapy (HBOT)

General definitionHyperbaric Oxygen Therapy (HBOT) delivers 100% oxygen at elevated ambient pressure in a specialized chamber as an adjunctive treatment to promote tissue healing.

Therapeutic effectsAims to increase tissue oxygen tension, improve vascularity and cellularity, reverse hypoxia, and reduce delayed neurologic effects.

Use caseUsed as adjunctive therapy for specified indications (e.g., diabetic lower extremity wounds meeting criteria, osteoradionecrosis, certain acute ischemic conditions).